CGIX
$3.81
Cancer Genetics
($.12)
(3.05%)
CGIX
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Nov 18
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CGIX reports earnings?
Beat
Meet
Miss

Where is CGIX's stock price going from here?
Up
Flat
Down
Stock chart of CGIX
Analysts
Summary of analysts' recommendations for CGIX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.
Peers
MedtronicVarian Medical SystemsCONMED